Jehane Michael Le Grange

Jehane Michael Le Grange

Auto-generated profile, based on publicly available information

Jehane Michael Le Grange

The First Clinical College, Wuhan Union Hospital, Tongji Medical College, Huazhong University of Science and Technology, 1277 Jiefang Avenue, Wuhan, 430022, People's Republic of China

Research Focus & Metrics

Academic Career Length

8Years (2019-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
1 September 2019 in Global Health Journal
Verified
Journal Article
Open access
STShuo Tian
Shuo Tian
WYWenbo Yang
Wenbo Yang
JGJehane Michael Le Grange
Jehane Michael Le Grange
PWPeng Wang
Peng Wang
WHWei Huang
Wei Huang
ZYZhewei Ye
Zhewei Ye

1 August 2020 in Infection and Drug Resistance
Verified
Journal Article
Open access
PDF file
LMLing Ma
Ling Ma
WWWenjing Wang
Wenjing Wang
JGJehane Michael Le Grange
Jehane Michael Le Grange
XWXiaorong Wang
Xiaorong Wang
SDShuaixian Du
Shuaixian Du
JZJin-Nong Zhang
Jin-Nong Zhang
Purpose: To differentiate between respiratory infections caused by SARS-CoV-2 and other respiratory pathogens during the COVID-19 outbreak in Wuhan, we simultaneously tested for SARS-CoV-2 and pathogens associated with CAP to determine the incidence and impact of respiratory coinfections in COVID-19 patients. Patients and Methods: We included 250 patients who were diagnosed with COVID-19. RT-PCR was used to detect influenza A, influenza B and respiratory syncytial viruses. Chemiluminescence immunoassays were used to detect IgM antibodies for adenovirus, Chlamydia pneumoniae and Mycoplasma pneumoniae in the serum of patients. Based on these results, we divided the patients into two groups, the simple SARS-CoV-2-infected group and the coinfected SARS-COV-2 group. Coinfected patients were then further categorized as having a coinfection of viral pathogen (CoIV) or coinfection of atypical bacterial pathogen (CoIaB). Results: No statistically significant differences were found in age, gender, the time taken to return negative SARS-CoV-2 nucleic acid test results, length of hospital stays, and mortality between the simple SARS-CoV-2 infection group and the coinfection group. Of the 250 hospitalized COVID-19 patients, 39 (15.6%) tested positive for at least one respiratory pathogen in addition to SARS-CoV-2. A third of these pathogens were detected as early as the 1st week after symptom onset and another third were identified after more than three weeks. The most detected CAP pathogen was C. pneumoniae (5.2%), followed by the respiratory syncytial virus (4.8%), M. pneumoniae (4.4%) and adenovirus (2.8%). Patients coinfected with viral pathogens (CoIV) (n=18) had longer hospital stays when compared to patients coinfected with atypical bacterial pathogens (CoIaB) (n=21). Except for one fatality, the remaining 38 coinfected patients all recovered with favourable outcomes. Conclusion: Coinfections in COVID-19 patients are common. The coinfecting pathogens can be detected at variable intervals during COVID-19 disease course and remain an important consideration in targeted treatment strategies for COVID-19 patients.

11 June 2020 in Critical Care
Verified
Journal Article
Open access
PDF file
LGLili Guan
Lili Guan
LZLuqian Zhou
Luqian Zhou
JGJehane Michael Le Grange
Jehane Michael Le Grange
ZZZeguang Zheng
Zeguang Zheng
RCRongchang Chen
Rongchang Chen

23 November 2020 in Journal of Forensic Sciences
Verified
Journal Article
Closed access
PDF file
FHFang Huang
Fang Huang
SZShuquan Zhao
Shuquan Zhao
FTFang Tong
Fang Tong
YLYue Liang
Yue Liang
JGJehane Michael Le Grange
Jehane Michael Le Grange
YZYiwu Zhou
Yiwu Zhou

11 November 2019 in International journal of legal medicine
Verified
Journal Article
Closed access
PDF file
YLYue Liang
Yue Liang
FTFang Tong
Fang Tong
FHFang Huang
Fang Huang
YLYuluo Liu
Yuluo Liu
LZLonglong Zhu
Longlong Zhu
YZYiwu Zhou
Yiwu Zhou

29 July 2021 in Pharmacology Research & Perspectives
Verified
Journal Article
Open access
PDF file
XZXiao‐Fang Zheng
Xiao‐Fang Zheng
DCDan‐Dan Chen
Dan‐Dan Chen
XZXiao‐Ling Zhu
Xiao‐Ling Zhu
JGJehane Michael Le Grange
Jehane Michael Le Grange
LZLuqian Zhou
Luqian Zhou
JZJin‐Nong Zhang
Jin‐Nong Zhang
Chronic obstructive pulmonary disease (COPD) often tends to respond poorly to glucocorticoid (GC) therapy. Reduced Histone deacetylase‐2 (HDAC‐2) activity is an important mechanism behind this GC insensitivity. In this study, we investigated the effects of three phosphodiesterase inhibitors (PDEIs), with an anti‐inflammatory propensity, on cigarette smoke (CS)‐induced pulmonary inflammation and HDAC‐2 activity. Male C57BL/6 mice were exposed to cigarette smoke (CS) over the course of 30 weeks. Administration of the PDEIs commenced from the 29th week and followed a schedule of once daily treatments, 5 days a week, for 2 weeks. Roflumilast (ROF) was administered intragastrically (5 mg·kg−1), while pentoxifylline (PTX) (10 mg·kg−1) and theophylline (THEO) (10 mg·kg−1) were administered intraperitoneally, either alone or in combination with a GC (triamcinolone acetonide or TRI, 5 mg·kg−1, i.m., single injection). Lung morphometry, as well as the activity of HDAC‐2, pro‐inflammatory cytokines and reactive oxygen species (ROS) were assessed at the end of the 30‐week course. CS exposure was associated with a reduction in HDAC‐2 activity and the up‐regulation of ROS expression. PTX, ROF, and THEO administration led to the partial restoration of HDAC‐2 activity, which was favorably associated with the reduction of ROS expression. However, combining TRI to any of these PDEIs did not synergistically augment HDAC‐2 activity. Inactivation of HDAC‐2 due to long‐term CS exposure is closely related to exaggerated oxidative stress, and this reduced HDAC‐2 activity could partially be restored through the use of PDEIs. This finding provides a potential novel approach for further clinical research.